In 2026, the infant formula milk powder industry will usher in the peak of "full formula re-registration" review. The new national standard for HMOs (Breast milk oligosaccharides) has changed ingredients such as 2‘-FL and LNnT from “bonus points” to “must-answer questions”.
But an embarrassing reality is: the product side is already running, but the method side is still chasing.
In October 2023, the National Health Commission officially approved 2’-fucosyllactose (2’-FL) and lactose-N-neotetraose (LNnT) is added to infant formula as a "three new foods", and HMOs have entered the fast lane of compliance application. However, although the national food safety standard "Determination of Breast Milk Oligosaccharides in Food" has been approved as a project, it is still in the draft stage for comments and will take some time to be officially released.
At the same time, regulatory authorities have become increasingly strict in their review of the labeling of HMOs - the National Food Inspection Center clearly required in August 2026 that "HMO", "breast milk oligosaccharides" or similar suggestive expressions must not appear in labels. This means that companies can only rely on accurate quantitative testing data to support formula compliance, rather than relying on marketing rhetoric on labels.
The question arises: How to test HMOs? especiallyLNTThe "twins" of LNnT and LNnT have exactly the same chemical formula (C₂₆H₄₅NO₂₁). They only differ in the connection method between galactose and N-acetylglucosamine (β1-3 vs β1-4). Conventional C18 reversed-phase chromatography cannot separate them at all.
Come on, Wufeng Instruments will give you the answer!